CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-Small-Cell Lung Cancer Treated With TKI Crizotinib: A Proof-Of-Concept Study
Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2020.00057
Full Text
Open PDFAbstract
Available in full text
Date
February 18, 2020
Authors
Publisher
Frontiers Media SA